# What the Chinese and Japanese trials tell us about who was studied

- Article ID: research-360
- Product: Survodutide (survodutide-700)
- Canonical page: https://heritagebiolabs.com/research-library/articles/360-what-the-chinese-and-japanese-trials-tell-us-about-who-was-studied
- Product collection: https://heritagebiolabs.com/research-library/products/survodutide
- Product page: https://heritagebiolabs.com/product/survodutide-700
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

A peptide is a short amino-acid chain joined by peptide bonds. Peptides can be designed to engage receptors for signals that affect metabolism. Survodutide is an investigational peptide that acts at glucagon and GLP-1 receptors. Two 2026 design reports described how researchers set up randomized weight-management trials in China and Japan, including who could enroll and when outcomes would be measured. [1, 2]

The Chinese trial enrolled 306 adults under body mass index and obesity-related complication criteria described in its design. The researchers planned to assess average percentage change in weight and the proportion reaching at least a 5% reduction at week 52. The baseline report describes the group as it entered the study, including the prevalence of metabolic dysfunction-associated steatotic liver disease, abnormal blood lipids and other conditions. [1]

The Japanese trial enrolled 274 adults using different eligibility rules for obesity disease and related complications. Its two principal weight measures were planned for week 76, and investigators planned additional measurements of liver fat and body composition in a subset. The baseline paper reports how many participants already had diabetes, abnormal blood lipids or high blood pressure. Those details show which conditions were present before the interventions were assigned. [2]

A baseline percentage describes the people in a study before treatment. It cannot measure what changed as a result of treatment. These design papers provide context for later comparisons, including differences in eligibility and follow-up. Neither article reported the final treatment effects. Reading the protocols with eventual outcome papers helps ensure that a result is interpreted for the people and time point it actually represents. [1, 2]

## Sources

1. Linong Ji et al. Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN). Diabetes Therapy (publication 2026-08-14). <https://pubmed.ncbi.nlm.nih.gov/42599381/>
2. Koutaro Yokote et al. Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial. Diabetes, Obesity and Metabolism (publication 2026-05-31). <https://pubmed.ncbi.nlm.nih.gov/42219222/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 072 - SNAP-8 and Survodutide.docx; article 360; content SHA-256 4a975abfecd4e2262fa5f40294975e287b02d1378815e5a84b8faf828754aaa0.
